Prior concerns regarding a partial loss of GIP-R responsiveness in patients with T2D have been tempered by more recent studies suggesting that this defect may be reversible once blood glucose levels are reduced (e.g., by treatment with other drugs) [5], [8]. The gene discussed is GIPR; the disease is type 2 diabetes mellitus.